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Summary
The investigation of familial isolated hyperparathyroidism
(FIHP) has been greatly facilitated in recent years by the iden-
tification of the genes responsible for most cases of syn-
dromic familial hyperparathyroidism (HPT). Kindreds with ap-
parently isolated hyperparathyroidism have been evaluated
with clinical, biochemical, imaging and gene mutational tests
designed to recognize multiple endocrine neoplasia type 1
(MEN1), the hyperparathyroidism-jaw tumor syndrome (HPT-
JT), and familial hypocalciuric hypercalcemia (FHH). Approxi-
mately 100 kindreds with the apparent diagnosis of FIHP were
studied in clinical series that included screening by germline
DNA mutational testing of one or more of the genes for these
three syndromes since 1997. Of these provisionally diagnosed
FIHP kindreds, some 10 to 20% had occult MEN1 and roughly
10% each had unrecognized HPT-JT or an FHH-related disor-
der evidenced by mutation of the calcium sensing receptor.
Thus nearly 70% of FIHP kindreds are apparently non-syn-
dromic. Even accounting for the likely underestimation in this
group of syndromic causes for familial HPT due to shortcom-
ings in current clinical and gene mutational testing methods,
this finding suggests the majority of FIHP kindreds have no
currently recognized syndromic etiology. Further study of this
subset of carefully evaluated and apparently non-syndromic
FIHP kindreds should assist in the identification of novel
gene(s) important for neoplasia in the parathyroid and whose
mutation can result in the FIHP phenotype. 
KEY WORDS: hyperparathyroidism, FIHP, endocrine neoplasia, calcium-
sensing receptor, parafibromin.
Introduction
Familial isolated hyperparathyroidism (FIHP; HRPT1) is a diag-
nostic subgroup of familial hyperparathyroidism (HPT) that can
be non-syndromic or can result from the incomplete expression
of a syndromic form of familial HPT (Fig. 1). Syndromic forms
of familial HPT that can present as FIHP include multiple en-
docrine neoplasia type 1 (MEN1) (1, 2), familial hypocalciuric
hypercalcemia (FHH) (also known as familial benign hypercal-
cemia) (3, 4), and the hyperparathyroidism-jaw tumor syn-
drome (HPT-JT; HRPT2) (5). Multiple endocrine neoplasia type
2A (MEN2A) (2, 6, 7), unlike MEN1, is not typically a consider-
ation in the differential diagnosis of FIHP, because of the high-
er penetrance of medullary thyroid carcinoma and pheochro-
mocytoma than of HPT in MEN2A families. It is unknown how
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Figure 1 - The relationship as a Venn diagram among familial forms of
hyperparathyroidism that may present as familial isolated hyperparathy-
roidism (FIHP) [modified and updated from reference (11)]. The dashed
circle represents the set of patients presenting with the provisional diag-
nosis of FIHP. Contained entirely within this dashed circle is a subset of
families who have subsequently been thoroughly evaluated for, but lack
findings diagnostic of, MEN1, FHH and HPT-JT (FIHP (non-syndromic);
in a solid circle). Subsets of patients with incomplete expression of
MEN1, FHH and HPT-JT (the total set of patients in each syndrome rep-
resented by a solid circle) can also present with the FIHP phenotype. The
distinction between the FIHP category and the syndromic categories arbi-
trarily depends on the sensitivity of diagnostic tests used to detect the
syndrome. MEN2A is a familial form of hyperparathyroidism seldom if
ever presenting as FIHP. Within each circle representing a defined syn-
drome are included the genetic locus (or loci in the case of FHH) of the
syndromic trait and the responsible gene product. An asterisk next to the
genetic locus indicates that the gene and gene product are unknown for
the form of familial hyperparathyroidism mapping to this site. The relation-
ship among the patient groups is intended to be qualitative, and the area
of each circle and the area of overlap between circles are not intended to
be proportional to their encountered or predicted values. 
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many as yet unrecognized genotypes may also present as
FIHP (8).
MEN1 is an autosomal dominant disorder characterized by en-
docrine and non-endocrine tumors, most prominently involving
the parathyroids, enteropancreatic endocrine system, and pitu-
itary (1, 9). Because HPT is the earliest and most frequent en-
docrinopathy in MEN1, some kindreds with apparent FIHP rep-
resent early and/or occult expressions of MEN1. The gene re-
sponsible for MEN1 has been cloned (10), leading to gene mu-
tational analytical methods applicable to MEN1, FIHP, and oth-
er conditions (2, 8, 11).
FHH is an autosomal dominant trait usually causing mild HPT
with relative hypocalciuria (3, 4); hypercalcemia in FHH is highly
penetrant at all ages, even in the perinatal period (3). FHH cas-
es almost always remain hypercalcemic following partial or
subtotal parathyroidectomy (PTX) (3). Mild hypermagnesemia is
sometimes seen in FHH but is unusual in other forms of primary
HPT (3, 12). Most cases of FHH result from a loss-of-function
mutation in the gene for the calcium-sensing receptor (CaSR)
on the long arm of chromosome 3 (13-15). However two undis-
covered genes have been implicated in rare kindreds with FHH;
1 gene at chromosome 19p (16) and 1 gene at 19q (17).
HPT-JT syndrome is an autosomal dominant disorder with high
but incomplete penetrance of HPT. It may present with
parathyroid adenoma, parathyroid carcinoma, and/or fibro-os-
seous jaw tumors (5, 18). Renal cysts (19, 20) and solid renal
tumors (19, 21, 22) have also been associated with HPT-JT.
Cystic parathyroid tumors have been associated with HPT-JT
(23). HRPT2, the gene for HPT-JT, has been identified on the
long arm of chromosome 1 (24). FIHP with or without parathy-
roid carcinoma but lacking evident jaw tumors can result from
occult germline HRPT2 mutation (8, 25-27) as can apparently
sporadic parathyroid cancer (26, 28). Uterine tumors have
been suggested to be part of the HPT-JT phenotype (29), even
though demonstration of somatic HRPT2 mutation or loss of
heterozygosity (LOH) at 1q25-q31 in DNA from such uterine tu-
mors is still lacking. This contrasts with the level of evidence for
MEN1-associated uterine leiomyomata, in which most tumors
have demonstrable LOH at the MEN1 gene locus (30).
This mini-review will survey the clinical and molecular genetic
studies of FIHP kindreds reported since 1997 when the identifi-
cation of the MEN1 gene (10) allowed for the first time sensi-
tive evaluation of such families for occult germline mutation of
a gene predisposing to a familial form of HPT. Screening for
occult germline mutation of the CASR gene (13) and the
HRPT2 gene after its identification in 2002 (24) added to the
power of such analyses. Particular emphasis will be given to
the analysis of 40 kindreds from our own institution with a pro-
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Table I - Clinical characteristics and gene mutational screening results in 40 kindreds with a provisional diagnosis of familial isolated hyper-
parathyroidism, modified from previous reports (8, 11). The kindreds are grouped according to their final diagnostic classification as HPT-JT,
CASR-mutation-positive, or non-syndromic FIHP (8, 11).
Kindred Proband Index case testing results Notes
I.D. Number Age at Sex Gene mutational screening (b)
affected diagnosis
(a) of HPT
No. Tot. M F (Years) (M/F) MEN1 CASR HRPT2
Hyperparathyroidism-Jaw Tumor Syndrome Group
417 5 3 2 27 F N N exon 7 
679insAG
2862 7 2 5 48 M N N N c
27,000 2 1 1 10 F N N exon 1 d
34delAACATCC
35,900 4 3 1 34 M N N exon 7 e
679insAG
Calcium-Sensing Receptor Mutation-Positive Group
1214 2 2 0 26 M N exon 4 N
V268del-11X273
5780 11 7 4 53 F N exon 7 N
R886P
10,147 3 1 2 30 F N exon 4 N
R220W
23,300 3 2 1 21 M N exon 3 N
L159P 
28,300 2 1 1 53 M N exon 4 N
E250K
Familial Isolated Hyperparathyroidism Group
13 2 0 2 53 F N N N
225 2 0 2 43 F N N N
410 2 1 1 53 F N N N
4318 3 0 3 50 F N N N
5977 4 1 3 41 F N N N
continued
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visional diagnosis of FIHP and described in detail in two previ-
ous reports (8, 11) (Table I).
Occult MEN1 among kindreds provisionally diagnosed 
with FIHP
Tests of affected individuals from provisionally diagnosed FIHP
kindreds to identify occult MEN1 include blood testing of hor-
mone levels, imaging studies and gene mutational analysis.
Clinical studies of FIHP kindreds often utilize biochemical tests
and/or pituitary or pancreatic imaging to explore for incomplete
expressions of MEN1. Prior diagnosis of gastrinoma or pro-
lactinoma in the proband or any known affected relative in an
FIHP family was an exclusion criterion in the studies reviewed
here. Molecular genetic analysis of germline DNA for loss-of-
function mutation in the MEN1 gene (10, 31) is the most sensi-
tive test for occult MEN1 in FIHP kindreds. 
Taken together, series examining 2 or more FIHP kindreds
since the identification of MEN1 in 1997 have found occult
MEN1 mutation in nearly 20% of families (Table II). Our own
studies found no cases of occult MEN1 among 40 FIHP kin-
dreds (Table I) (8, 11), and no family initially characterized as
FIHP at study entry was subsequently reclassified as MEN1
and excluded. The typically small size of FIHP kindreds in our
studies precluded 11q13 linkage analysis as a test for undiag-
nosed MEN1 mutation. 
The identification of MEN1 as the etiology for FIHP in none of
the kindreds in our series may relate partly to the high average
age (39 years) at diagnosis among the FIHP probands (8, 11).
The penetrance of all neoplasms in familial tumor syndromes
must increase with age, and by age 40 at least 1 non-parathy-
roid endocrine tumor is expressed in the majority of MEN1 pa-
tients (32).
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Kindred Proband Index case testing results Notes
I.D. Number Age at Sex Gene mutational screening (b)
affected diagnosis
(a) of HPT
No. Tot. M F (Years) (M/F) MEN1 CASR HRPT2
6324 2 1 1 61 F N N N
6325 3 2 1 45 M N N N
6326 2 0 2 61 F N N N
6335 2 1 1 39 F N N N
7751 3 0 3 19 F N N N
8715 4 0 4 49 F N N N
9462 2 2 0 37 M N N N
10,021 2 0 2 74 F N N N
10,157 2 1 1 40 F N N N
21,300 3 1 2 34 F N N N
24,200 2 0 2 44 F N N N
24,700 3 2 1 43 M N N N f
25,200 2 1 1 51 M N N N
26,500 3 1 2 30 F N N N
27,300 3 0 3 29 F N N N
28,200 8 5 3 14 F N N N g
28,400 2 1 1 43 M N N N
28,500 2 1 1 52 F N N N
28,600 2 0 2 12 F N N N
28,700 2 1 1 20 F N N N
28,800 2 1 1 54 F N N N
28,900 3 2 1 28 M N N N
30,300 2 0 2 18 F N N N
33,100 2 1 1 73 M N N N
33,800 2 1 1 66 M N N N
35,100 2 1 1 51 M N N N
(a) The total (Tot) number of affected refers to the number of individuals in a kindred with biochemically documented HPT, except for kindred 2862 with HPT-JT,
in which that number also includes 1 euparathyroid individual with characteristic fibro-osseous jaw tumors. (b) N, or normal results in one of these three columns
indicates that no mutations, i.e. sequence alterations affecting transcript splicing or protein coding, in the tested gene were found. (c) Kindred 2862, originally
considered as FIHP by Streeten et al. (46), had negative HRPT2 mutational testing but could be clearly diagnosed as HPT-JT after the presence of bilateral re-
nal cysts and cemento-ossifying fibromas in several affected members was determined (8, 11). This kindred also had members with a rare T445A polymorphism
in the CASR coding region (11). (d) Kindred 27,000 was previously described (11) and listed as kindred-24 in Table I of Carpten et al. (24). (e) Kindred 35,900
was previously described (8) and is not known to be related to either kindred 417 (11) [listed as kindred-01 in Table I of Carpten et al. (24)] or kindred-33 (24)
with the identical mutation in exon 7 of HRPT2. (f) Kindred 24,700 was previously described with a case of parathyroid cancer in the context of FIHP (62). (g)
The pedigree for, and further information about, kindred 28,200 is presented in figure 2.
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Some 31 different kindreds with a provisional diagnosis of
FIHP have been reported in the literature to have germline mu-
tations of the MEN1 gene (Table III). The types and distribu-
tions of MEN1 mutations in these 31 FIHP kindreds are similar
to those in typical MEN1 families (33). One mutation was recur-
rent in 2 apparently unrelated FIHP families, a D418H mis-
sense mutation in exon 9 (34, 35). It has been previously ob-
served that a significant excess of germline missense/in-frame
mutations was present among FIHP kindreds with MEN1 gene
mutation compared to mutation-carrying MEN1 families (36).
As more such FIHP families are reported, this significant differ-
ence in germline missense/in-frame mutation frequency be-
tween FIHP and MEN1 groups has persisted (FIHP, 47%;
MEN1, 28%; p < 0.05) (Table III) (33, 37). This suggests that
MEN1 gene mutations that encode truncated, frame-shifted, or
null protein products are more penetrant in non-parathyroid tis-
sues resulting in more frequent pituitary and enteropancreatic
tumors and a clinical picture recognizable as MEN1. Interest-
ingly several MEN1 mutations identical to those reported in
FIHP kindreds (Table III) have been found in families with full
phenotypic expression of MEN1 including 359del4 (33, 38-41),
E363del (33), and R527X (33). Long term follow up of some
kindreds with germline mutation of MEN1 and initially charac-
terized as FIHP revealed the development of pituitary and/or
enteropancreatic tumors typical of MEN1 that were not evident
at the initial evaluation (42). Since HPT is usually the earliest
and most penetrant feature of MEN1 (1), evaluation of only
younger MEN1 mutation carriers at the time of kindred ascer-
tainment may lead to a provisional diagnosis of FIHP.
Testing directed at recognizing FHH among kindreds 
provisionally diagnosed with FIHP
Several tests of affected individuals from provisionally diag-
nosed FIHP kindreds have been utilized to exclude families
that might have unrecognized or atypical FHH (Table II) (8, 11,
27, 34, 35). These tests include blood testing of calcium, mag-
nesium and PTH levels and determination of renal calcium and
creatinine clearance (3, 4). Review and extension of pedigrees
to look for evidence of hypercalcemia in members under the
age of 10 improves sensitivity for the detection of FHH, as
does CASR gene mutational analysis (11).
Series examining 2 or more FIHP kindreds have found occult
CASR gene mutation in some 12% of the total reported fami-
lies (Table II). Our own studies found 5 cases of occult CASR
mutation among 40 FIHP kindreds (Table I) (8, 11), and Warn-
er et al reported 4 cases of CASR mutation in their series of 22
FIHP families (34). 
Interestingly, the index cases and other affected members of
CASR mutation-positive kindreds initially considered as FIHP
often had clinical features atypical of FHH. For example,
probands from 3 of the 5 FIHP kindreds diagnosed as CaSR
mutation-positive in our studies were hypercalciuric, as were
members of 2 of 4 such kindreds in the Warner et al series
(11, 34). Nephrolithiasis was reported in affected members in
4 of 9 CaSR mutation-positive kindreds initially considered as
FIHP in the 2 studies (11, 34). Two probands presented with
intact PTH values >150 pg/ml, more than two times above the
value reported to discriminate between FHH and other forms
of HPT (43). Eucalcemia in affected members more than 4
years following subtotal parathyroidectomy, an outcome un-
usual among FHH patients, was also reported in 2 of 4 CaSR
mutation-positive kindreds initially considered as FIHP (34).
Several clinical findings among affected members supported
the diagnosis of FHH in CaSR mutation-positive kindreds ini-
tially considered as FIHP, despite the presence of hypercalci-
uria and nephrolithiasis in several probands. Hypercalcemic in-
dividuals from 3 FIHP kindreds subsequently categorized as
CaSR-mutation positive demonstrated mild hypermagnesemia
(11), a finding seen in FHH but not in other forms of familial
HPT (3, 12). Very significant differences were observed when
the mean serum magnesium levels among tested hypercal-
cemic members of provisionally-diagnosed FIHP kindreds
found to be CaSR mutation-positive was compared with that
from members of HPT-JT or non-syndromic FIHP kindreds
(11). One CASR mutation-positive kindred initially considered
as FIHP revealed clear features of FHH including relative
hypocalciuria in other affected members (n = 4), hypercalcemic
members less than 10 years old (n = 4), mild hypermagne-
semia in hypercalcemic members (n = 4), and persistent hyper-
calcemia following subtotal parathyroidectomy (n = 2), even
though the proband was hypercalciuric (11). 
Some nine different kindreds with a provisional diagnosis of
FIHP have been reported in the literature to have germline mu-
tations of the CASR gene (11, 34). As in typical FHH, missense
amino-acid substitutions make up the vast majority of germline
CASR mutations in kindreds initially considered as FIHP (Table
IV). The distribution of missense mutations among the extracel-
lular, 7-transmembrane, and intracellular domains of the CASR
in these FIHP kindreds does not differ significantly from those
in typical FHH families (44). The R220W CASR mutation in one
kindred provisionally diagnosed as FIHP (11) was previously
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Table II - Syndromic causes of hyperparathyroidism identified among
series of kindreds with a provisional diagnosis of FIHP studied by ge-
ne mutational and clinical testing since 1997. Only studies that analy-
zed two or more FIHP kindreds are included. The three genes that
account for most cases of syndromic familial HPT are shown (MEN1,
CASR, and HRPT2 (HPT-JT), see text) with the number of positive
and total kindreds tested in parentheses below each gene. In the
MEN1 gene testing column, 20 out of 107 FIHP kindreds tested posi-
tive since 1997 (19%), but only 8 of 76 kindreds (10%) tested positi-
ve in the more recent studies since 2002 that included testing for all
three syndromic HPT genes (8, 11, 27, 34, 35).
FIHP Year MEN1 CASR HPT-JT Ref Notes
series (+/total) (+/total) (+/total)
1 1997 00/500 (33) a
2 1998 00/400 (38)
3 2000 01/500 (63)
4 2000 02/200 (67)
5 2002 02/700 (68)
6 2002 02/400 (42)
7 2002 01/200 (69)
8 2003 04/700 (70)
9, 10 2002, 00/400 5/40 4/40 (8, 11) b
2004
11 2004 05/220 4/22 0/22 (34)
12 2004 00/700 0/70 2/70 (27)
13 2004 1/30 (26)
14 2006 03/700 0/70 0/70 (35)
Totals 20/107 9/76 7/79
(%) (19%) (12%) (9%)
(a) The results from this study (33) were not included in the MEN1 column
total since the same five kindreds were subsequently studied in more depth
and reported separately (8, 11). (b) The two studies from our center exami-
ning a total of 40 provisionally diagnosed FIHP kindreds (see also Table I)
were combined into one entry in this table (8, 11).
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reported in an apparently unrelated typical FHH kindred (15).
The R886P mutation maps to the predicted carboxyl-tail of the
CASR; a nearby mutation, F881L, was reported in a kindred
with FIHP and including some members with features quite dif-
ferent from FHH (45).
Occult HPT-JT among kindreds provisionally diagnosed
with FIHP
The principal clinical tests of affected individuals from kindreds
provisionally diagnosed as FIHP to identify incomplete forms of
HPT-JT are jaw and renal imaging studies. Prior diagnosis in
the proband or any known affected relative in a family with iso-
lated HPT of cemento-ossifying fibroma of the maxilla or
mandible, the jaw tumor type characteristic of HPT-JT (5), was
sufficient to make a presumptive diagnosis of HPT-JT and ex-
clude them the analyses of FIHP kindreds reviewed here (8,
11, 26, 27, 34, 35). The initial evaluation of one kindred (family
2862) included jaw imaging of the proband only, with normal
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Table III - Kindreds with familial isolated hyperparathyroidism and germline MEN1 gene mutation from the literature.
Kindred Affected MEN1 Germline Mutation Ref
No. No. Sex Exon/ Intron Base Consequence
(M/F) (IVS) (a) (b) (c)
1 4 4/0 2 359 359del4 (64)
2 2 - 2 365 365ins19 (34)
3 3 - 2 369 369ins18 (63)
4 3 0/3 2 444 V112L (68)
5 2 0/2 3 568 D153V (70)
6 4 3/1 3 639 639del4 (70)
7 3 2/1 3 661 V184E (71)
8 - - 3 700 T197I (34)
9 8 3/5 3 764 abnl splicing (72)
10 7 3/4 4 873 E255K (58)
11 14 6/8 4 889 Q260P (57)
12 3 2/1 IVS4 894-9 abnl splicing (35)
13 4 4/0 5 910 L267P (73)
14 3 1/2 IVS5 934+1 abnl splicing (35)
15 7 5/2 6 940 P277H (42)
16 3 1/2 7 1124 G305D (74)
17 2 2/0 7 1157 1157del4 (70)
18 2 - 8 1167 1167del3 (34)
19 3 1/2 8 1169 Y353X (75)
20 6 3/3 8 1197 E363del (36)
21 3 2/1 8 1206 E366X (67)
22 4 2/2 9 1341 A411P (70)
23 4 4/0 9 1350 L414del (65, 76)
24 - - 9 1362 D418H (34)
25 2 1/1 9 1362 D418H (35)
26 11 3/8 IVS9 1460+1 abnl splicing (77)
27 5 2/3 10 1483 1483del4 (67)
28 - - 10 1656 1656ins1 (34)
29 8 4/4 10 1658 1658del1 (68)
30 3 2/1 10 1689 R527X (42)
31 5 1/4 10 1785 1785del1 (69)
(a) Exon or intron (IVS) number refers to numbering of exons in the MEN1 gene (10). (b) Base numbering adjusted to conform to cDNA for human menin (Gen-
Bank locus XM 006532) and differs from numbering in several original literature citations (63-65). (c) Consequence of gene mutation shown as: del, deletion;
ins, insertion; abnl splicing, disruption of putative exon-intron splice junction; missense or nonsense mutation (in single letter amino acid code, where X = Stop).
“-” indicates data not available. MEN1, multiple endocrine neoplasia type 1.
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findings, leading to a provisional diagnosis of FIHP (46). Sub-
sequent investigation revealed that 3 siblings in this kindred
developed jaw lesions, in each case determined to be cemen-
to-ossifying fibrous tumors by histopathologic analysis, leading
to its re-categorization as HPT-JT (Table I) (11). One affected
member of kindred 27,000 had had multiple mandibular and
maxillary surgeries to remove jaw “cysts” decades earlier; med-
ical records documenting the histopathology could not be re-
trieved (Table I) (11). Subsequent analysis of germline DNA in
this FIHP kindred documented HRPT2 frameshift mutation
(Table I) (24).
Renal imaging, usually by ultrasonography, is routinely per-
formed on affected members of kindreds provisionally diag-
nosed with FIHP since cysts (19, 20) and solid renal tumors
(19, 21, 22) have been associated with HPT-JT. In studies
from our center, bilateral renal cysts were found in individuals
from three kindreds initially considered as FIHP but subse-
quently categorized as HPT-JT (Table I; kindreds 417, 2862
and 27,000), while no such bilateral cysts were found in CaSR
mutation-positive or non-syndromic FIHP kindreds (8, 11). No
renal hamartoma, nephroblastoma or renal cell carcinoma, le-
sions also reported in occasional association with HPT-JT (19,
21, 22), has been reported among provisionally diagnosed
FIHP kindreds (8, 11, 26, 27, 34, 35). The probands from 2
non-syndromic FIHP kindreds had renal angiomyolipoma diag-
nosed by ultrasound and/or CT scan (11). Such renal tumors
have been rare concomitants of MEN1 (47, 48).
Review of the surgical findings and histopathology of parathy-
roid tumors from operated members of provisionally diagnosed
FIHP kindreds may add evidence for their re-consideration as
occult HPT-JT. Cystic parathyroid tumors have been associat-
ed with HPT-JT (5, 23) and parathyroid tumors from some kin-
dreds initially considered as FIHP and later recognized as in-
complete expressions of HPT-JT were noted to have cystic
features (8, 11, 24, 26, 27, 49). At least one FIHP kindred with
cystic parathyroid tumors in several affected members, howev-
er, has negative germline HRPT2 gene mutational testing and
no other features to date suggestive of HPT-JT (Fig. 2) (11,
50). Parathyroid cancer is common in HPT-JT (51-53), but very
rare among sporadic cases of HPT (0.8%) (54). In this light, it
is interesting to note that the presence of parathyroid carcino-
ma in some kindreds initially considered as FIHP foreshad-
owed their subsequent recognition as expressions of HPT-JT
(8, 11, 25, 46).
Germline DNA analysis for HRPT2 gene mutation may also
identify occult HPT-JT among provisionally diagnosed FIHP
kindreds even though such testing has only some 50% sensi-
tivity in full-featured HPT-JT families (24). Five unique germline
HRPT2 mutations have been identified in eight kindreds initially
considered as FIHP (Table V). Three of these mutations are re-
current: a point mutation at a splice junction in HRPT2 IVS1
that uncovers a cryptic exon 1 donor splice site (49) in two ap-
parently unrelated families with isolated HPT (26, 49); an exon
2 L64P missense mutation in two unrelated FIHP families (24,
25, 27); and a 2-bp insertion in HRPT2 exon 7 in three appar-
ently unrelated FIHP kindreds (8, 11, 29, 55). The latter exon 7
mutation (679insAG) has also been described in the germline
of patients with full-featured HPT-JT (24) and seemingly spo-
radic parathyroid carcinoma (28). The types of germline
HRPT2 mutation in kindreds initially considered as FIHP re-
semble those in HPT-JT with the majority resulting in frameshift
or splicing abnormalities that cause incomplete parafibromin
protein expression (Table V) (24).
Diagnostic approach to FIHP kindreds
Based on the findings from our studies and others reviewed
here, it is possible to offer a practical approach for managing
patients and families with FIHP, for which an obvious syn-
dromic etiology has been excluded. Sporadic cases of HPT, on
the other hand, must be evaluated according to standard rec-
ommendations (56). In the context of FIHP, the first step is to
review the medical, dental and surgical history of the proband
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Figure 2 - A kindred with non-syndromic familial isolated hyperparathy-
roidism, cystic parathyroid tumors, and negative germline HRPT2 gene
mutation testing. This kindred (28,200) with non-syndromic FIHP has
been previously reported (8, 11) (Table I). Individuals II-6 and III-5 were
separately reported earlier as the father and daughter in Shallow and Fry
(50). Filled symbols indicate individuals with primary HPT, and a “C” indi-
cates that cystic parathyroid tumors were noted at surgery. Original surgi-
cal records and parathyroid histopathology reports were not available for
individuals II-2, II-6 and II-3. Square symbols indicate males, and round
symbols indicate females. A diagonal slash mark through the symbol
means the individual is deceased. The arrow indicates the proband.
Table IV - Kindreds with familial isolated hyperparathyroidism and
germline CASR gene mutation from the literature. 
Kindred CASR Germline Mutation Ref
No. Exon Base Consequence Affected domain
(a) (b) (c) (d)
1 3 299 T100I ECD (34)
2 3 476 L159P ECD (11)
3 4 658 R220W ECD (11)
4 4 748 E250K ECD (11)
5 4 801 V268del-11X273 na (11)
6 4 1008 K336del ECD (34)
7 7 1949 L650P 7TM (34)
8 7 2065 V689M 7TM (34)
9 7 2657 R886P ICD (11)
(a) Exon number refers to numbering of exons in the CASR gene (13) as de-
scribed in the calcium-sensing receptor locus-specific database (44). (b) Ba-
se numbering starts from initiation codon. (c) Consequence of gene mutation
shown as: del, deletion; missense mutation (in single letter amino acid co-
de). (d) Location in predicted receptor protein domain according to the “ve-
nus flytrap model” (66): ECD, extracellular domain; 7TM, seven transmem-
brane region; ICD, intracellular, or cytoplasmic, domain; na, not applicable.
CASR, calcium-sensing receptor.
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and all available affected members. This careful review should
emphasize features of MEN1 (recurrent HPT, ulcers, and pitu-
itary tumors), features of HPT-JT (parathyroid cancer, fibrous
jaw tumors, kidney cysts or tumors), and features of FHH (un-
successful parathyroid surgery, rare urolithiasis and possible
hypermagnesemia in hypercalcemic members, and hypercal-
cemia in cases below age 10).
If this focused review of systems is negative, the next step is to
examine the renal calcium clearance-to-creatinine clearance
ratio in all available hypercalcemic members. At the same time
obtain blood calcium (preferably ionized) from as many untest-
ed first-degree relatives as possible, including young children
in this process; any newly identified hypercalcemic members
should also be checked for relative hypocalciuria. Imaging
studies for gnathic and renal features of HPT-JT should be ob-
tained on all hypercalcemic members at this point.
Gene mutational testing to confirm or further exclude the in-
complete expression of a syndromic form of familial HPT can
then be pursued. Specific gene tests screening for CASR,
MEN1 and HRPT2 mutation are all commercially available in
CLIA-approved laboratories. CASR mutation testing can be
sought early or late in the workup of the FIHP kindred. MEN1
mutation testing and periodic blood hormone testing for occult
gastrinoma or prolactinoma may be worthwhile, particularly in
FIHP patients who continue to appear non-syndromic. Similarly
HRPT2 gene mutation testing and periodic orthopantography
of the jaw and renal ultrasound can be considered in affected
individuals from FIHP kindreds lacking syndromic features.
If 7 or more affected members are available and the diagnosis
is still uncertain, then genetic linkage could be pursued, focus-
ing on loci for the known familial HPT syndromes on chromo-
somes 3q, 1q25-31, and 11q13. Because the number of affect-
ed family members is often small, a definitive syndromic diag-
nosis is often not possible. Such non-syndromic FIHP families
should then be followed with each of the three main syndromic
diagnoses in mind.
Distribution of genotypes presenting as FIHP
All reported kindreds so far with the phenotype of FIHP that
have undergone successful linkage analysis have had their
trait linked to either the MEN1 locus on 11q13 (57, 58), the
HPT-JT locus on 1q25-31 (20, 59), the CASR gene locus on
3q (45), or FHH-related but unknown gene loci on 19p (16) and
19q (17). These families each had available for genetic analy-
sis at least 7 affected members or obligate gene carriers, the
lower limit of cases necessary to give a significant linkage
score. The small number of affected individuals precludes ge-
netic linkage in many non-syndromic FIHP families (11). 
Because of the less frequent expression of non-parathyroid
features in HPT-JT compared to MEN1, a larger proportion
with the former syndrome might be expected to present as
FIHP. Yet the combined data from surveys of provisionally di-
agnosed FIHP kindreds shows occult cases of MEN1 are
identified about twice as often as HPT-JT (Table II). This may
be due in part to problems of initial kindred ascertainment. As
discussed above, consideration of mostly younger affected
members at the time of kindred ascertainment may obscure
the initial recognition of MEN1 and lead to a provisional diag-
nosis of FIHP. This is because HPT is usually the earliest and
most penetrant feature of MEN1 (1). Another reason for the
unexpectedly low number of incomplete expressions of HPT-
JT recognized among FIHP kindreds might be the low sensi-
tivity of current PCR-based HRPT2 gene mutation testing
methods (24).
The prevalence of FHH-related disorders may also be under-
estimated in studies of provisionally diagnosed FIHP kindreds.
No mutation in the CASR gene has been demonstrated in the
probands from as many as 1/3 to 1/2 of kindreds with FHH trait
linked to chromosome 3q (60, 61). Furthermore a small num-
ber of FHH kindreds have a trait that is not linked to the CASR
locus at chromosome 3q (16, 17). Thus germline DNA screen-
ing of the CASR gene is helpful but is not presently a definitive
tool to rule out FHH. For these reasons and because relative
hypocalciuria is not always present in each affected member of
CASR mutation-positive kindreds, it is likely that the prevalence
of FHH-related syndromes is underestimated in current analy-
ses of FIHP kindreds (8, 11, 27, 34, 35).
Novel genes in the etiology of FIHP
It is unknown how many as yet unrecognized genotypes may
also present as FIHP (8). Among 76 families initially consid-
ered as FIHP in 5 recent clinical studies that investigated for
germline MEN1, CASR and HRPT2 gene mutation, 53 families
or nearly 70% have no currently recognized syndromic etiology
(Table II) (8, 11, 27, 34, 35). Others and we may still be under-
estimating the number of non-syndromic FIHP kindreds within
this 70% that will ultimately be transferred into 1 of the 3 known
syndromic categories. Since the strength of an exclusionary di-
agnosis for a syndrome in any family depends on the size of
the family, and the degree of thoroughness in the identification
and testing of all affected members, it is necessarily more diffi-
cult to exclude syndromic diagnoses in smaller kindreds. In our
series the number of affected per kindred was smaller in the
non-syndromic than the syndromic FIHP subgroups (11). The
number of affecteds was also small in non-syndromic families
in other recent FIHP series (27, 34, 35). This supports the pos-
sibility that additional syndromic families have not been identi-
fied.
Nevertheless a core subset of non-syndromic kindreds likely
will remain even after the future optimization of molecular diag-
nostic tools to detect occult MEN1, HPT-JT and FHH-related
syndromes. This strongly suggests that novel gene(s) exist
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Table V - Kindreds with familial isolated hyperparathyroidism and
germline HRPT2 gene mutation from the literature. 
Kindred HRPT2 Germline Mutation Ref Note
No. Exon/ Base Consequence
Intron
(IVS)
(a) (b) (c)
1 1 34 34 del7 (8, 11) d
2 IVS1 131+1 abnl splicing (26, 49)
3 2 191 L64P (24, 25, 27)
4 IVS2 237+1 abnl splicing (27)
5 7 679 679ins2 (8, 11, 29, 55) e
(a) Exon or intron (IVS) number refers to numbering of exons in the HRPT2
gene (24). (b) Base and amino acid numbering starts from initiation codon.
(c) Consequence of gene mutation shown as: del, deletion; ins, insertion;
abnl splicing, disruption of putative exon-intron splice junction; missense mu-
tation (in single letter amino acid code). (d) Kindred 27,000 was previously
described (11) and listed as kindred-24 in Table I of Carpten et al. (24). (e)
This 2-bp insertion in HRPT2 exon 7 has been reported in three apparently
unrelated FIHP kindreds (8, 11, 29, 55) and also in the germline of patients
with classic features of HPT-JT (24) and seemingly sporadic parathyroid car-
cinoma (28).
F MILI L_Simonds  23/10/2006  13.04  Pagina 181
whose mutation can result in the FIHP phenotype. If so, then
the samples and data collected from the subsets of thoroughly
evaluated, apparently non-syndromic FIHP kindreds should as-
sist in the identification and characterization of an unknown
number of novel genes important for neoplasia in the parathy-
roid. Genome-wide linkage analysis of the trait predisposing to
HPT among well characterized apparently non-syndromic FIHP
kindreds would be a logical starting point in this search (78).
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